Treatment to Target Using Recombinant Interleukin‐1 Receptor Antagonist as First‐Line Monotherapy in New‐Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five‐Year Follow‐Up Study

OBJECTIVE: Systemic juvenile idiopathic arthritis (JIA) is a multifactorial autoinflammatory disease with a historically poor prognosis. With current treatment regimens, approximately half of patients still experience active disease after 1 year of therapy. This study was undertaken to evaluate a tr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Arthritis Rheumatol
Main Authors: ter Haar, Nienke M., van Dijkhuizen, E. H. Pieter, Swart, Joost F., van Royen‐Kerkhof, Annet, el Idrissi, Ayman, Leek, Arjen P., de Jager, Wilco, de Groot, Mark C. H., Haitjema, Saskia, Holzinger, Dirk, Foell, Dirk, van Loosdregt, Jorg, Wulffraat, Nico M., de Roock, Sytze, Vastert, Sebastiaan J.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Pediatric Rheumatology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6617757/
https://ncbi.nlm.nih.gov/pubmed/30848528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40865
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados